Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Substantial doubt about the company's ability to continue as a going concern.
“Despite the actions undertaken by management to improve liquidity and operating costs—including increased commercial activity, cost and pricing improvement initiatives, commercialization of newly cleared medical products, equity financing activities, proceeds from warrant exercises subsequent to quarter-end, and other working capital initiatives—management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of one year from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 5, 2026
Conference · 2026-02-04
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Our next presenting company is Syntex, a company developing advanced ceramic technology across multiple industries with us today is Eric Olson, the chief executive officer and Greg Honeybloom, the chief investment officer. Gentlemen, please go ahead.
Thank you, everybody, for joining us. My name is Greg Honeybloom. I'm the Chief Investment Officer, and I have a 35-year investment banking career, of which, about 20 years ago, the original founders walked into my office in New York City and showed me this very interesting biomaterial. They thought it had great applications for orthopedic implants, and I ended up providing the first hundred million dollars in equity, private equity, to this company prior to its public offering in 2014 with J&P Securities. We have pioneered the use of silicon nitride as an advanced biomaterial for the use as an ideal biomaterial. Silicon nitride has been around for 100 years in an industrial application known for its prized properties of being very strong and wear resistant, but we have uncovered and developed the biological and surgical uses of silicon nitride as an ideal biomaterial. Syntex, you know, Eric and I were recruited by the former board of directors about 15 months ago to come back into the company to help reposition it and launch a new generation of products utilizing our technology. We have the only FDA audited and certified, ISO-certified manufacturing facility in the world capable of developing silicon nitride, and we also have a robust patent portfolio and a great management team and a strong board of directors that have been recently sat, that all have luminaries in the industry, that have great medical device industry experience. So, since we got here 15 months ago, we have accomplished quite a bit. We divested of all the non-medical-related assets. We stabilized the balance sheet with $12 million. We replaced the board of directors, as I indicated, including Chris Lyons, sat with Medtronic for 15 years in the medical device arena for Medtronic. We also acquired a company by the name of Synaptic, who was developing a foot and ankle wedge system that we were going, that they wanted us to OEM, but we decided to acquire them so we can have complete control of that product, and we filed that 510K, and we received that FDA clearance just in, just, just in October. Also, to help kind of develop our technology for medical implants to actually a platform technology, we received two patents in September for the use and method of embedding silicon nitrite in fibrous materials for wound dressings and sutures. But most importantly, the transpired in early December and gave us great validation as we signed an agreement with Evonik. Evonik is like the 3M of Europe. They're the second largest manufacturer of medical grade polymers in the world, and we are co-developing with them our silicon nitrides fused with their peak to develop next generation AI-assisted 3D implants. And I'll turn it over to Eric.
So the history of biomaterials for devices is dominated primarily by the use of metals and plastic, titanium and stainless steel and various forms of plastics. The material has been widely accepted. It works very well. However, there are some weaknesses with the materials, primarily the ability to see radiographically the material and the surrounding bone or soft tissue, And then also the large percentage of infections that occur with medical devices that could be attributed to either the metal or plastic. It ranges about 20% of implants fail because of issues related to infection. So our company has developed what we believe is the ideal biomaterial. Silicon nitride is a bioactive ceramic material. There are currently only four manufacturers in the world that can manufacture medical-grade ceramic materials. Three of them all manufacture the same type of ceramic. It's ZTA ceramic that's used for femoral heads for total hip replacements. Silicon nitride is very unique, and we have very specific material claims that we've been able to get clearance from the FDA, and I'll go through these specific claims, which are very strong, we believe. So the chemical components of silicon nitride are naturally occurring in the body. The silicon nitride is bioinert, meaning it doesn't cause a harmful interaction. It provides clear radiographic visibility, unlike a metal where you get radiographic scatter or artifacts that prohibit the surgeon from seeing the surrounding bone when you're trying to obtain a fusion, and or plastics that disappear with radiograph, and you can't determine where the implant is. Silicon nitrate demonstrates antimicrobial activity, a very strong claim, and we believe is one of the most important aspects of the material. It also promotes bone fusion. It's not only osteoconductive, but it's also osteogenic, and it really mimics natural bone. The look and feel, the modulus of elasticity is very similar to standard cortical cancellous bone. And we also received the claim of a potential to decrease the likelihood of revision surgeries due to infection. We can manufacture silicon nitride in various formulations. We can manufacture monolithic ceramic either with standard subtractive manufacturing or with 3D printed capabilities. We can add silicon nitride to other composites, peak, peck, and carbon fiber, which gives the material characteristics to those materials. We can also coat metal with silicon nitride, and we can manufacture powder that's specifically used for fabrics, fibers, and for plastics that can benefit with those characteristics as well. There's very many vertical markets that can benefit from silicon nitride, obviously orthopedics and spine, but also textiles, wound dressing, PPE, sutures, filters, et cetera, can benefit from the characteristics of silicon nitride. And one area that we are really focused on in our commercial strategy is patient-specific and custom implants, trauma, oncology, and other specific orthopedic procedures as well. We manufacture all of the silicon nitride in our 2,200-square-foot facility in Salt Lake City. We are FDA on visa audited. We are ISO 13485 and ISO 9001 certified. And we are the only company that can manufacture medical grade silicon nitride. There is proprietary know-how that allows us to do this, and not only to do medical grade, but also to get the specific characteristics, the antimicrobial and osteoconductive characteristics, We have over 20 patents to date, and we also have 180-plus peer-reviewed author papers that have been published. Most recently, we received FDA clearance on a family of foot and ankle implants, and we think this is an ideal application for silicon nitride in that most of these procedures are done with immune-compromised patients, patients that have poor health, either diabetic or other issues, And the implants are used to help and aid in getting effusion in a bone that is either weak or mushy. And without the ability to do the procedure, have an effective outcome with effusion and not get an infection, there's potential for patients to lose a limb because of those issues. We have recently signed a supply agreement with Evonik. This is a kind of a game-changing opportunity for us. The supply agreement allows us to manufacture the filament that is used for 3D printing, as well as the standard rod stock and sheet stock peak material that can be used for current implants, which would include, again, interbody devices and trauma applications. This is a very large, validating relationship that took us several years to be able to perfect, and we're very excited about the announcement, and we think it'll have a significant impact as we move forward with licensing of the material to Evonik and other companies. Our short-term strategy includes expanding our use of silicon nitride for fusion procedures. Obviously, the foot and ankle wedge we will launch here in the next 30 to 45 days. We also have a short-term strategy on patient-specific implants that we can do very quickly. The nature of custom and patient-specific implants, when you're doing it on a one-to-one patient, you don't have to go through a lengthy clinical trial to launch that to the market, and then companion biologics that will help with the aid in the fusion of the procedures. Our short-term strategy with patient and custom implants, patient-specific and custom implants include going after specific foot and ankle procedures, trauma, revisions, oncology, and pediatric applications. We also, as I mentioned, we are very focused on 3D printing of the silicon nitride peak material, and the reason for this, the growth in 3D printing has been augmented by the use of AI engineering that will allow us to rapidly prototype and design the implants. The traditional model has been, for example, if you get a titanium plate after a trauma, what will occur is a doctor will take a CT or MRI scan, send it to a manufacturer, and it'll take six to eight weeks to be able to get a metal implant shipped back to the hospital for implantation. Meanwhile, the patient is suffering in ICU waiting for the implant and outcomes are reduced because of potential for infection and other issues. The way that we can now 3D print silicon nitrite peak with obviously has been augmented with AI assistance, but also with these small printers that can allow us to not only print patient specific implants at our facility here in Salt Lake City, but also point of care in the hospital. So as if you can imagine, if you're a patient, a trauma patient, and you have a choice of waiting six to eight weeks to get a metal plate in your head or to get a ideal silicon nitride material within 24 to 48 hours printed in the facility itself, we believe this is going to dramatically improve outcomes over time. We now have gone beyond being just a specific medical device company to a platform technology with the recent patents that we've obtained that allows us to use silicon nitride embedded to fibrous materials. And we are focused short-term on a couple of animal trials to allow us to begin the work on licensing silicon nitride for suture and for wound dressing. And we anticipate that by third or fourth quarter this year, we will have potential licensees identified and potentially be able to sell those technologies in those vertical markets here very soon. We have a very experienced leadership team, all with a great medical commercialization experience. Same with our board of directors. And I'll turn it back to Greg to finalize the discussion.
So we have no debt on our balance sheet. We have access to an ATM if we want to use it. We also have some more outstanding. We just started telling the story literally about six weeks ago because many of our valuation drivers really transpired from October when we received our FDA clearance for our foot and ankle that we're launching literally in a month. And also with our patents to expand it into fibrous materials for wound dressings and sutures, and also the Evonik deal was transformative from just an elevation and an optical standpoint that we're getting quite a lot of inbound interest from a lot of interested parties from a variety of opportunities. We've been on a couple non-deal roadshows over the last couple weeks, and the opportunities among us for having financial options to be very specific, making sure we control the cap table. When we did our pipe about a year ago, Eric and I raised 75% of that money. We know where every share is. They're all long-term holders, and we're looking for shareholders that have a long-term horizon to come in and take a meaningful position in the company, and I think he'll be very, very happy. As we begin to make some significant announcements over the coming quarters that will have a dramatic impact on the visibility and aspects of the company's technology that needs to be showcased.
Thanks, Greg. Robert, do you want to open it up for questions?
Yes, I'd like to begin with the first question.
Sure.
And thank you for that presentation. Very interesting. And the reduction in morbidity and mortality in orthopedics is one of the things that I would expect to be driving sales. One of the questions, though, is in terms of when you make this, it sounds as if this is a coding, but is it something that is a material that's substitute? For existing or something that's added on in addition?
Well, yeah, we can, as mentioned earlier, we can manufacture it in a number of different formulations. We can do a block of silicon nitride ceramic, and then with subtractive manufacturing kind of design the shape of the device. So that would be 100% silicon nitride, right? We can do that. Also, 3D printing. We can 3D print it. So again, the entire device would be silicon nitride. We can also do it as a composite, where you add silicon nitride into peak, peck, or carbon fiber, and then the silicon nitride is embedded completely within the material and has the same characteristics, but is a composite, and it's a little different and more easily printable in some of these mini 3D printers. And then the powder formulation. And then you're right, we can coat metals with silicon nitride as well, which obviously will benefit those, you know, those implants.
Okay, and what is the cost comparison between a product made with your materials and the standards that are out there now?
Well, it's substantially less expensive than metals. It does increase the price of peak materials when it's embedded slightly, but it's very inexpensive for us to add it to other applications. So the only other comparable, I think, was like, for example, suture. Silver has shown some antimicrobial characteristics, and so there is silver-impregnated sutures, as you know, Robert. And so, but silicon nitride embedded suture would be vastly less expensive than silver. And then also for implant manufacturing, we can manufacture with 3D printing these implants far less expensively than we could when we did subtractive manufacturing, and the yield goes up dramatically as well. In fact, typically it takes about, we can do 400 implants per month with one machine. With 3D printing, we can do 400 implants per machine per day. So the yield goes up very dramatically with the advent of 3D printing, which is just really going to change the market, we believe, in medical devices.
Yeah, just listening to this, it sounds like the reduction in infections and these other benefits that you described would be a superior. product to what's out there and justify a premium, but you're coming in as a competitive on price or less. Right. Sounds great.
Yeah, our commercial strategy is to come out not with premium pricing. At this point, we obviously want to get market uptick. Initially, you know, the material has been known for a while. It the, you know, but we've just got this recent FDA clearance for the foot and ankle, which As I mentioned, it's a great indication for this material. I mean, it's just, if you're a diabetic patient and you get an infection, it is really very dangerous for the patient. So to have a material that's innately antimicrobial is really critical. And we think the uptick for our foot and ankle wedges will be very rapid. We're excited about that launch.
Yeah, just for diabetics alone, I can see a tremendous advantage. For sure. So, speaking of adoption, have you released any sales numbers or given any kind of guidance for the coming year and first 12 months?
No, we haven't given any guidance yet because we're getting ready to launch our products with, you know, a limited use release for the foot and ankle here in about a month and a half. So we've got, you know, about 15 doctors who will do that, and then on to 60 doctors in the third and fourth quarter. And it's really hard to, you know, extrapolate the fact of what some of these licensing opportunities are among us also. So we just have been very, very protective of providing any guidance until we have a little bit more visibility in the coming quarters.
Okay, good. All right, and you mentioned certain milestones in that answer. Are there any others that we can look forward to, maybe applications in oncology or any of the textile applications?
Yes, we are actually commencing a study for the textiles for wound dressings and sutures that actually is ongoing as we speak right now with a very well-known consultant group. They're all past FDA groups that are doing the study. We expect to have that news probably in April, May. We also feel like we'll do some additional commercial opportunities that we'll be able to announce also.
Terrific. Okay, we can take any questions from the floor if there are any. Or Okay, just in terms of some of these other licensing applications and strategy, are there any things that you would point to on the horizon in terms of applications or ways that you're going to be using the product or potential licensing on the horizon, either strategic or corporate events that you would point to?
Well, I mean, we are focused on licensing the silicon nitride peak. Obviously, we believe that could occur, you know, in the near future. And then the licensing of the silicon nitrite for suture and for wound dressing. Those are the animal trials that we've initiated, and we'll have that data soon, and we'll be able to begin discussions with groups about licensing that material for those applications. We do. We're getting a lot of inbound requests for applications, but we're really kind of trying to stay focused on, you know, I think if you look at our revenue drivers coming up, you know, about a third of our revenue will come from our inner body devices, our foot and ankle devices. Another third will be from patient specific. The revenues is strong. The reimbursement is, you know, is anywhere from 10 to 50,000 per implant based on the size and shape. So good reimbursement. And then the other bucket, the other third is these license agreements. And that we anticipate that, you know, this year through next year, we'll have rapid growth in all those market segments. So Terrific.
Okay, if there are any other points or any things that you'd like to say to wrap up. Please go ahead.
Well, Robert, we appreciate the time and your invitation to this conference. We hope it's beneficial. If you have any requests for information, please contact us. We're very interested in looking for partners to assist us in the development of this technology. And most importantly, we're really excited about the potential to benefit patients' lives, and we're excited about the technology. So thank you for the time.
And one other thing. Thank you for presenting. I'll be looking forward to following these events as they unfold over the next year.
Thanks, Robert.
Thank you.